Rationale: In prostate cancer (PCa) patients, the Tumor-to-Blood ratio (TBR) has been validated as the preferred simplified method for lesional 18F-DCFPyL (a radiolabeled Prostate-Specific Membrane Antigen (PSMA) ligand) uptake quantification on positron emission tomography (PET).